Open original FDA record ↗Recall record
- FDA identifier
- Z-0725-2017
- Company in FDA record
- Randox Laboratories, Limited
- FDA record creation date
- Dec 8, 2016
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
According to the firm, Carry over was observed when the amylase or pancreatic amylase test is run directly before or after the Magnesium assay. An update is required to the RX Imola analyser running order and an acid wash recommended when setting up the magnesium assay. A correction was made to the IFU for the Magnesium assay and all RX Imola customers in the USA were contacted with the updated instruction.
Source facts
- Action
- Randox sent an Urgent Field Safety Notice to all affected consignees. The letter identified the product, the problem, and the action to be taken by the customer. Customers were advised to review and update Rx Imola running order where required. Rework any remaining stock with updated IFU and Important Notice. Complete and return the vigilance response section of the form to technicalservikces@randox.com.
- Initiated
- 2016-04-14
- Root cause
- Device Design
- Terminated
- 2017-09-19
- Distribution
- Nationwide Distribution The product was only distributed to US Consignees.
- Recall number
- Z-0725-2017
- Recall status
- Terminated
- CDRH record ID
- 149845
- FDA record created
- 2016-12-08
- Recall event number
- 75263